首页> 外文OA文献 >LncRNA PVT1 Associates with c-Myc and Stabilizes Oncogenic Signaling in Prostate Cancer
【2h】

LncRNA PVT1 Associates with c-Myc and Stabilizes Oncogenic Signaling in Prostate Cancer

机译:LncRNA PVT1与c-Myc相关联并稳定前列腺癌的致癌信号

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Understanding the factors that affect c-Myc in prostate cancer is critical to developing an effective means of treatment for aggressive, castration-resistant forms of the disease. Myc is an oncogene known to be overexpressed and stabilized in many types of cancer, prostate included. Recent insights into breast cancer have revealed that Myc protein retains a longer half-life in cancer cells, but the cause for this has yet to be deduced. Due to its close proximity and proven interaction with Myc, I propose that the lncRNA PVT1 is stabilizing Myc and facilitating its activation of target genes in castration-resistant prostate cancer.udTo explore this hypothesis, metastatic prostate cancer DU145 cells were transfected with both siRNAs and ASOs targeting PVT1. Cells were analyzed for changes in different protein levels, as well as binding partners, through the use of immunoprecipitation and western blot. These results were verified with RT-qPCR data to confirm knockdown levels of PVT1. Proliferation assays were also conducted to explore the proliferative abilities of cells when PVT1 levels were decreased. udTransfection of PVT1 with siRNA yielded about a 50% knockdown, while ASO targeting brought PVT1 levels down 80%. PVT1 inhibition had different effects on the level of c-Myc in cells depending on the method of transfection used--while transfection with anti-PVT1 siRNAs slightly decrease the amount of c-Myc protein in the cell, transfection using ASOs significantly increases c-Myc. Most importantly, proliferation of DU145 cells decreased with PVT1 knockdown by ASOs. Removal of this lncRNA, therefore, hinders that oncogenic potential for growth of prostate cancer cells. udSince Myc poses a difficult target for cancer therapy, any new method to mitigate its oncogenic signaling would be invaluable. Targeting lncRNA PVT1 may be a successful method of doing just that, but more work needs to be done to explore the effects of different knockdown strategies. It is clear, however, that the relationship between Myc and PVT1 is a convoluted interaction that warrants further research. A breakthrough in this area could lead to huge improvements in the way prostate cancer is diagnosed and treated.
机译:了解影响前列腺癌中c-Myc的因素对于开发针对侵略性,去势抵抗性疾病的有效治疗手段至关重要。 Myc是已知在许多类型的癌症(包括前列腺癌)中过表达和稳定的癌基因。最近对乳腺癌的见解表明,Myc蛋白在癌细胞中保留了更长的半衰期,但其原因尚待推论。由于它与Myc的亲密关系和已被证实的相互作用,我认为lncRNA PVT1可以稳定Myc并促进其在去势抵抗性前列腺癌中的靶基因活化。以及针对PVT1的ASO。通过使用免疫沉淀和蛋白质印迹,分析细胞中不同蛋白质水平以及结合伴侣的变化。用RT-qPCR数据验证了这些结果,以确认PVT1的敲低水平。还进行了增殖测定以探讨当PVT1水平降低时细胞的增殖能力。用siRNA转染PVT1产生的敲低约50%,而靶向ASO的PVT1水平降低了80%。 PVT1抑制对细胞中c-Myc的水平有不同的影响,具体取决于所使用的转染方法-用抗PVT1 siRNA进行的转染会稍微减少细胞中c-Myc蛋白的量,使用ASO进行的转染会显着增加c-我的C。最重要的是,DU145细胞的增殖随着ASO的PVT1抑制而降低。因此,这种lncRNA的去除阻碍了前列腺癌细胞生长的致癌潜力。 ud由于Myc对癌症治疗提出了困难的目标,因此减轻其致癌信号的任何新方法都是无价的。靶向lncRNA PVT1可能是一种成功的方法,但是需要做更多的工作来探索不同敲低策略的效果。但是,很明显,Myc和PVT1之间的关系是一个复杂的相互作用,值得进一步研究。在这一领域的突破可能会导致前列腺癌的诊断和治疗方式取得巨大进步。

著录项

  • 作者

    Jones Rachel;

  • 作者单位
  • 年度 2017
  • 总页数
  • 原文格式 PDF
  • 正文语种 en_US
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号